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Introduction
Amikacin (C
22
H
43
N
5
O
13
) is a semisynthetic aminogly-
coside antibiotic. In medical applications, amikacin is 
commonly used to treat acute respiratory exacerbations 
in patients with cystic fibrosis, intra-abdominal sepsis, 
complicated urinary tract infections, and other infections 
caused by gram-negative enteric bacilli, or other gram-
positive bacteria such as Mycobacterium (McCracken 
1986; Duff 2002; Ji et al., 2006). Though amikacin is gen-
erally considered safe for human use at recommended 
doses, its therapeutic window is pretty narrow, an acute 
overdose or even a normal dose can lead to severe side 
effects such as hearing loss as well as liver and renal 
damages (Forge and Schacht, 2000; Martínez-Salgado 
et al., 2007; Taylor et al., 2008). Amikacin is assigned a 
pregnancy risk class D designation by the US Food and 
Drug Administration (FDA), meaning that there is posi-
tive evidence of human fetal risk but potential benefits 
may warrant use of the drug in pregnant women despite 
potential risks (Berglund et al., 1984; Lacy et al., 2010). In 
particular, amikacin can cross the placenta and may have 
potential risk for the developing embryo (McCracken, 
1986; Pacifici, 2006). Thus, the developmental toxicity 
and the teratogenic effect of amikacin are important 
issues that should be investigated.
Studies using animal models have shown that 
continuous infusion (16 mg/kg) or intra-muscular 
injections of amikacin (60 mg/kg) in rabbit but little 
or no nephrotoxicity was observed (Brion et al., 
1984). In rodents, amikacin treatment causes kidney 
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We used zebrafish as a model to assess amikacin-induced embryotoxicity. We exposed zebrafish embryos to 
amikacin, using different amikacin doses (0–10 ppm), durations (12–48 h), and onsets (0, 24, 48 hpf ). Amikacin-
induced embryonic toxicity and reduced survival rate were found dependent on the exposure dose, duration and 
onset. Based on immunostaining with neuron-specific antibodies, amikacin reduced the number and size of zebrafish 
neuromasts. In addition, Amikacin caused pelvic, dorsal and anal fin defects in dose-dependent and duration-
dependent manners. Proliferating cell nuclear antigen immunostaining revealed that amikacin-induced fin defects 
were not due to reduction of proliferating mesenchymal cells. TUNEL assay demonstrated that amikacin-induced fin 
defects might not associate with apoptosis. Therefore, further investigations are required to elucidate if other cell 
death pathways are involved in amikacin-induced fin defects.
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dysfunctions (ex: polyuria, proteinuria, enzymuria, 
and decreases in urine osmolality) as well as hair cell 
damages (Rankin et al., 1980; Aran et al., 1995). In 
humans, overdose of amikacin can cause nephrotoxic-
ity and ototoxicity (Lerner et al., 1977; Luft et al., 1981; 
McCracken 1986; Begg and Barclay, 1995). Although 
the current therapeutic dose of amikacin (15 mg/kg) is 
safe in adult, may increase the risk of toxicity in infant 
(Siddiqi et al., 2009). These observations suggest that 
amikacin-induced toxicities might differ depending 
on the species, the route, the dose, and the duration of 
exposure. Several alternative methods developed using 
cell, organ or whole embryo cultures are available for 
investigating the embryo toxic and/or teratogenic 
potential of amikacin (Schaad et al., 1988; Amacher 
et al., 1989; Lass et al., 1989; Kotecha and Richardson, 
1994; Chang et al., 1995; Wang et al., 1996). However, 
it is highly disadvantageous that subtle changes dur-
ing early embryonic development are difficult to 
observe using mammal model; thus, development of 
an  alternative animal model is essential.
In contrast to other vertebrate models, zebrafish 
embryos are fertilized externally, having large amount 
of transparent embryos, and their early development 
can be easily observed that makes it an effective model 
for toxicological studies (Westerfield, 1995; Chen et al., 
2011). To further investigate the amikacin-induced 
subtle defects, we conducted a series of time- and 
dose-response amikacin exposure experiments using 
zebrafish as a model. This strategy is excellent for 
studying amikacin-induced teratogenicity during early 
embryonic development.
Materials and methods
Fish embryos staging and amikacin treatment
Mature zebrafish (AB strain) was raised at the zebrafish 
facility of the Life Sciences Development Center, 
Tamkang University. The fish were maintained at 
28°C with a photoperiod of 14 h light and 10 h dark, in 
an aquarium supplied with freshwater and aeration 
(Chen et al., 2009a). Embryos were produced using 
standard procedures and were staged according to 
standard criteria: hours postfertilization, hpf; or days 
postfertilization (dpf; Westerfield, 1995). Amikacin 
(25 mg/ml; Tai Yu Pharmaceutical Co., Taiwan) was 
diluted in sterile distilled water to the appropriate 
concentrations. Six exposure protocols (methods I–VI) 
were applied in the amikacin treatment experiments 
according to their exposure durations (Figure 1A). 
For dose titration, zebrafish embryos were collected, 
randomly divided into several groups (30 embryos 
per group), and exposed to either water (no treatment 
control) or water containing amikacin at selected con-
centrations (0–10 ppm). All embryos were cultured 
in 6-well cell culture plates with 5 ml solution each, 
and survival rates were counted at the check point. 
All animal experiments in this study were performed 
in accordance with the guideline issued by regional 
 animal ethic committee.
Fin morphology recording
To develop a quantitative assessment of fin morphology, 
fins of amikacin-treated fish were compared with fins of 
healthy, untreated fish and subjectively classified as (i) 
normal: at least 90% of the fin was intact, (ii) reduced: 
20–90% intact, and (iii) absent: less than 20% intact 
(Wang et al., 2009a, Chen et al., 2011).
Antibody labeling
Proliferating cell nuclear antigen (PCNA) (Santa Cruz, 
USA) and anti-acetyl tubulin (Sigma, USA) were employed 
to visualize proliferating cells and neuron cells, respec-
tively, as previously described (Wang et al., 2009b). For 
antibody staining, embryos were fixed in 4% paraform-
aldehyde in phosphate buffer saline (PBS, pH 7.0) for 4 h 
at room temperature. Embryos were then washed in PBS 
twice for 15 min each, soaked in 100% acetone at −20°C 
for at least 10 min, and rehydrated with 0.1% (v/v) Tween 
20 in PBS (PBST) three times for 15 min each. After rehy-
dration, the embryos were treated with PBS containing 
5% goat serum albumin for blocking, and then subjected 
to immunofluorescence staining.
TUNEL assay
To detect cells undergoing programmed cell death, we 
performed terminal deoxynucleotidyl transferase [TdT]-
mediated deoxyuridinetriphosphate [dUTP] nick end 
labeling (TUNEL) experiment as described before (Chen 
et al., 2009a; Peng et al., 2010). By 96 hpf (48 h after expo-
sure with amikacin, method IV), embryos from mock 
control (fish from the same population of embryos but 
were not treated with amikacin) and 10 ppm of amika-
cin were fixed overnight at 4°C in 4% paraformaldehyde 
and TUNEL was performed using the In Situ Cell Death 
Detection kit (Roche, Switzerland).
Cryosection, histology and images
The procedures for cryosection and hematoxylin/
eosin Y (H/E) staining have been described previously 
(Wang et al., 2008; Chen et al., 2009b; Pai and Chen, 
2010). All embryos and sections were observed under a 
microscope (DM 2500, Leica) equipped with Nomarski 
differential interference contrast optics and a fluores-
cent module having green fluorescent protein (GFP), 
red fluorescent protein (DsRed), and 4′6-diamidino-
2-phenylindole·2HCl (DAPI) filter cubes (Kramer 
Scientific). Images of embryos were captured at specific 
stages with a digital carema (Eos550D, Canon).
Statistical analysis
All analyses and survival curves in this study were carried 
out by Matlab software (version 7.7.0). The median dosage 
levels (LC
50
 values) for different exposure methods were 
separately predicted by logistic regression analysis. The 
dosage, exposure time, and starting exposure time effects 
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on survival rate were also examined by logistic regression 
method. A significance level of 0.05 was used in all statisti-
cal analyses. The two-sample t-test with a significance level 
of 0.05 was employed to explain the significant difference 
between the treatment and control samples.
Results and discussion
Titration of amikacin dose and analysis of  
survival rates
To address the dosage and exposure-time effect of amika-
cin on the teratogenic incidence, we first treated zebrafish 
embryos with different dosages of amikacin (0, 2, 5, 10 ppm) 
and exposure-times (0–24, 0–48, 0–72, 0–96 hpf) via four 
experiment protocols (methods I–IV; Figure 1A) to investi-
gate the survival rates. Figure 1B depicts the mean survival 
rate and its standard error (SE) at each dosage level for four 
exposure design groups. For example, 92.7 ± 2.4% (mean 
± standard error, SE; n = 30, number of embryos tested in 
each group; N = 5, repeated five times) of the mock control 
embryos were alive at the check points of each method (I: 
24 hpf; II: 48 hpf; III: 72 hpf; IV: 96 hpf); and 64.0 ± 2.4% 
~ 54.7 ± 2.7% (n = 30, N = 5) of the embryos were alive after 
exposure to 2–10 ppm of amikacin for 48 h (method II). As 
shown in Figure 1B, similar phenomena that the survival 
rates decreased apparently when the dosage of amikacin 
increased were also observed for other exposure design 
groups (methods I, III, IV). In fact, the logistic regression 
analysis based on whole data reported the dosage and 
exposure-time effects are negative with p-values 0.0000 
and 0.0045 respectively, indicating a significant decrease 
in survival rates when amikacin concentration or exposure 
time increases. In addition, for each exposure method, we 
employed the logistic regression analysis to calculate the 
median dosage level (LC
50
 value) at which the survival rate 
exactly achieves 50%. Logistic regression assumes that the 
survival probability p is related to dosage level x by the 
logit function:
p x e x( ) ( )= + − − −1 0 1 1 
 and the median dosage level is thus given by
p− = −1 0 10 5( ). / 
Figure 1. Exposure protocols and survival rate analysis in this study. (A) Exposure methods of amikacin treatment in this study. Six 
types of exposure methods were designed for the amikacin treatment experiments according to the exposure durations and onsets; I: 
0–24 hpf, II: 0–48 hpf, III: 0–72 hpf, IV: 0–96 hpf, V: 24–72 hpf, and VI: 48–96 hpf. (B) Survival rates of zebrafish embryos after exposure to 
water (mock control) or water containing 2, 5, 10 ppm of amikacin when the exposure methods I–IV or (C) methods II, V, VI were used. 
The X- and Y-axes represent developmental stages and survival rates, respectively.
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 The predicted LC
50
 values for exposure methods I–IV are 
10.2, 9.5, 8.5, 6.6 ppm, respectively, indicating the longer 
exposure time induces the lower dosage to achieve half 
survival rate.
To investigate the effect of the starting exposure time, 
we further conduct two experiments (methods V, VI; 
Figure 1A), in which the same exposure time period (48 h) 
with method II remained but different starting times (24 
or 48) were considered. Figure 1C presents the mean 
survival rate and the SE of mean at each dosage level for 
exposure methods II, V, VI. The corresponding predicted 
LC50 values are 9.5, 28.9, 13.5 ppm, respectively. The 
logistic regression analysis based on whole data from 
methods II, V, VI reported the dosage effect and the start-
ing exposure time effects on survival rate among three 
exposure methods are significant (all p-values < 0.0001).
Loss of neuromasts and fin reduction are the obvious 
defective phenotypes of zebrafish embryos after 
exposure to amikacin
Previous studies have shown that hearing loss is 
one of the adverse effects after amikacin treatment 
(Taylor et al., 2008). The hair cells in the neuromasts 
of zebrafish share both morphological and functional 
similarity to those of the mammalian inner ear (Chiu 
et al., 2008). Here, we examined the phenotypic defects 
caused by amikacin using method VI. At 96-hpf, neu-
romasts are easily observed in the head as well as in 
the trunk regions of no treatment control embryo 
(Figure 2A and B). In contrast, no neuromasts are 
observed in the 10-ppm amikacin-treated embryos 
(Figure 2C and  D), indicating that amikacin is toxic 
for neuromasts development. The average number of 
neuromasts for no treatment control and amikaicn-
treated groups is 10.93 (0.07, n = 40; SE, sample size) 
and 0.42 (0.16, n = 40), respectively. A two sample t-test 
reported a significant difference between two groups 
(p-value < 0.0001). This result suggests that amikacin-
induced ototoxicity in zebrafish is similar to that in 
mammals; and 10-ppm, 48 h exposure is suitable for 
studying amikacin-induced teratogenicity in zebrafish. 
Besides loss of neuromasts, we found amikacin-exposed 
embryos also displayed an unexpected teratogenic 
defect, fin-reduction phenotype, including dorsal, 
ventral and pelvic fins shrinkage or absence (Figure 3A 
vs. 3B and 3C). These fin-reduction phenotypic defects 
were the most obvious consequence of amikacin expo-
sure in this animal model.
Amikacin-induced fin-reduction phenotypes are  
dose-dependent
Fin-reduction phenotypic changes were classified as 
“normal”, “reduced”, and “absent” according to the 
affected areas of fins on each embryo. The percentages of 
fish with normal, reduced, and absent fins after treatment 
with 0–10 ppm amikacin were quantified and it was found 
that, as the exposure dosages of amikacin increased, the 
percentages of fish with malformed (reduced plus absent) 
fins increased. At the end points (72 hpf), no embryos 
displayed malformed fins (reduced plus absent) after 0, 
2, 5 ppm of amikacin exposure using method V (24–72 h). 
The percentages of malformed fins slightly increased 
to 12.0 ± 2.3% (n = 30, N = 9) when the dose increased to 
10 ppm (Figure 3D). On the other hand, the fin-malfor-
mation rates significantly increased to 32.7 ± 8.2% (n = 30, 
N = 9) after 10-ppm amikacin exposure by method VI 
(48–96 hpf; Figure 3E), but no “fin-reduction defect” was 
observed when exposure protocol method II (0–48 hpf) 
was applied (data not shown). These observations clearly 
indicated that amikacin-induced fin-reduction pheno-
types of zebrafish embryos depended on their exposure 
onset and exposure dose.
The most evident adverse effects of amikacin are 
ototoxicity and nephrotoxicity; here, we found a novel 
Figure 2. Zebrafish embryos were stained with anti-acetyl tubulin antibody to make neuromasts visible. Embryos were exposed to water 
(mock control: 0 ppm of amikacin, A, B) or water containing 10 ppm of amikacin (C, D) by methods IV. After exposure, embryos were 
stained with anti-acetyl tubulin antibody to label all neurons, especially neuromasts. All the photos were taken from the lateral view and 
were of developmental stages at 96 hpf.
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and unexpected teratogenic defect, fin reduction, which 
hasn’t been reported in mammal model so far. In this 
regard, we applied method V with another aminogly-
coside antibiotic, gentamicin, to observe whether fin 
reduction is amikacin-specific teratogenic defect. Results 
showed that the percentages of malformed fins signifi-
cant increased to ≈60% after 5 ppm gentamicin treatment 
(data not shown). These observations indicate that fin 
reduction might be general malformed phenotypes after 
aminoglycosides antibiotic treatment, but more exposure 
data should be accumulated.
Treatment with amikacin does not affect proliferating 
fin mesenchymal cells
Investigation of the possible target cells attacked by ami-
kacin, which in turn cause fin-reduction phenotypes, was 
extended using cryosectioning and hematoxylin (H)/
eosin Y (E) staining to visualize cell nuclei/cytoplasm in 
the mock control and amikacin-treated embryos. In mock 
control embryos, there were numerous nuclei located at 
the fin/soma junctions (Figure 4A, B, C, and 4D, black 
arrows), and distributed evenly on the fins. In the amika-
cin-treated embryos, the number of nuclei located on fins 
Figure 3. Amikacin-induced fin malformation phenotypes are dose-response. Phenotypic changes after amikacin exposure: (A) normal 
fins, control, (B) reduced fins and (C) absent fins. Dashed lines in each figure indicate the morphology of fins. (D) Phenotype percentages 
of zebrafish embryos after amikacin treatment (0, 2, 5, 10 ppm) were illustrated when the exposure methods V (E) and VI (F) were used. 
The X- and Y-axes represent concentrations of amikacin and phenotype percentages, respectively. Data are presented as means ± standard 
error.
Figure 4. Histological features of amikacin-treated embryos. Transverse sections of mock (A–D) and amikacin-treated embryos (E–H) 
at trunk regions (96 hpf ) were stained with hematoxylin/eosin Y, and their fin mesenchymal cells around the soma/fin junction were 
indicated by arrows.
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appeared unchanged in comparison with mock  control 
embryos (Figure 4B, red arrows). Furthermore, mock 
control and amikacin-treated embryos were stained with 
monoclonal antibodies against PCNA, a proliferating cell 
marker. The results showed that the numbers of PCNA-
positive cells were unchanged between mock control 
and amikacin-treated embryos (Figure 5A, A′, A″ vs. 
5B, B′ B″). These observations clearly indicated that fin 
reduction is not a consequence from reduced number of 
proliferating fin mesenchymal cells.
Amikacin-induced cell apoptosis is the main cause  
for loss of neuromasts phenotype, but not for  
fin reduction
Experimental evidence accumulated from previous 
studies has shown that aminoglycoside can generate 
free radicals within the inner ear, that are potentially 
destructive to any or all cell constituents, resulting 
in apoptotic cell death and permanent hearing loss 
(Wu et al., 2002; Selimoglu 2007). We have demon-
strated that number of proliferating fin mesenchymal 
cells are unaffected after amikacin (Figure 5); thus, 
our hypothesis is that amikacin-induced loss of neu-
romasts and reduced-fin phenotypes of zebrafish 
embryos may be through cell apoptosis. Next, we car-
ried out TUNEL experiments and results showed that 
no apparent apoptotic signals were observed in the 
embryos derived from mock control group (Figure 6A). 
In  contrast, almost all neuromasts underwent apopto-
sis after amikacin treatment (Figure 6B, black arrows), 
indicating that amikacin-induced ototoxicity may share 
the same mechanism between mammals and zebrafish. 
On the other hand, we surprisingly found that TUNEL-
positive signal did not appear on fin mesenchymal cells 
(Figure 6B), suggesting that apoptosis might not be the 
main cause for reduced-fin phenotypes. In this regard, 
we hypothesize that amikacin treatment might activate 
other unknown cell death pathway, and consequently 
cause fin reduction.
Comparison of amikacin exposure doses among 
different species
For amikacin treatment in adult human, the appropri-
ate multidose regimen is 5.0 mg/kg actual weight every 
Figure 5. Effects of amikacin on proliferating fin mesenchymal cells. Embryos derived from mock control (A, A′, A”) or amikacin-treated 
groups (B, B′, B′) stained with antibodies against PCNA. Cryosections of A′ and B′ were counter-stained with DAPI. Panels A″ and B″ were 
merged figures of A, A′ and B, B′, respectively.
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8 h or 7.5 mg/kg actual weight every 12 h. The single daily 
dose should be 15 mg/kg ideal body weight (Duff 2002). 
In this study, we used single dose (10 ppm) for two days 
(method VI, 48–96 hpf). It is difficult to compare tox-
icities between species where one group is receiving the 
dose in the diet and the other is systemically exposed to 
a solution of the toxin, but we can still estimate the daily 
exposure of zebrafish embryos using appropriate calcu-
lations. The total amount of 2–10 ppm of amikacin in 5 ml 
solution is around 10–50 µg. In this study, 30 embryos 
received 10–50 µg of amikacin for 2 days, so the average 
daily exposure of each embryo is 0.17–0.83 µg of ami-
kacin if the absorption rate is 100%. The body weight of 
each zebrafish embryo is around 1.2 mg. Thus, the daily 
exposure of zebrafish embryos was around 136–691 mg/
kg (0.17–0.83 µg/1.2 mg). This is an extremely high dose 
in comparison with the recommended daily dose of ami-
kacin in adult people (15 mg/kg). However, the terato-
genic dosages of amikacin in zebrafish embryo should 
be acceptable in comparison with those used in rodents 
for toxicological studies (500–1000 mg/kg; Daudet et al., 
1998; Parietti et al., 1998; Murillo-Cuesta et al., 2010). 
Thus, we suggest that 2–10 ppm of amikacin, exposure for 
48 h is effective in this current model.
In conclusion, amikacin-induced malformation 
of fins could be easily observed in vitro during early 
embryogenesis in the present model. This could pro-
vide novel insights into the subtle changes induced by 
amikacin, which are worthy of further tests in higher 
vertebrates.
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